HinsBet BioChaperone insulin: Phase IIa data

A double-blind, crossover Phase IIa trial in 36 Type I diabetics showed that a single 0.2 U/kg dose of HinsBet met the primary endpoint of improving the rate of early insulin exposure vs. a single 0.2...